Targeting <scp>RNA</scp> modifications in leukaemia: Epitranscriptomic drugs are the new kids on the block
In this article, Chen et al. show that a chemical modification of transfer RNA, along its corresponding RNA modifier enzyme, is diminished in acute myeloid leukaemia. These findings further support the role of an aberrant epitranscriptome in haematological malignancies. Commentary on: Chen et al. Hydroxy-wybutosine tRNA modifications as indicators of disease progression and therapeutic targets in leukemia. Br J Haematol 2025; 206:517-530.
Authors
- Manel Esteller (ORCID: https://orcid.org/0000-0003-4490-6093)
Institutions
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Josep Carreras Leukaemia Research Institute (ES)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- British Journal of Haematology
- Published
- 2024-11-10
- DOI
- https://doi.org/10.1111/bjh.19894
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00